Ruibo Biology-B (06938): Positive Phase 2A research results for core product VORTOSIRAN targeting CAD.

Wisdom Financial APP news, Ruibo Biotech-B (06938) announced that the company announced the positive results of the phase 2a study of vortosiran (RBD4059), a small interfering RNA (siRNA) therapy targeting coagulation factor XI (FXI) in patients with chronic coronary artery disease (CAD) in Europe at the Global New Drug Conference held in Shanghai.